• 主题
高级搜索  >
历史搜索 清空历史
首页> 美国卫生研究院文献>World Journal of Gastroenterology >Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma
【2h】

Clinical value of serum CA19-9 levels in evaluating resectability of pancreatic carcinoma

机译：血清CA19-9水平在胰腺癌可切除性评价中的临床价值。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务，本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文，但由于OA文献来源多样且变更频繁，仍可能出现获取不到、文献不完整或与标题不符等情况，如果获取不到我们将提供退款服务。请知悉。
页面导航
  • 摘要
  • 著录项
  • 相似文献
  • 相关主题

摘要

AIM: To evaluate the clinical value of serum CA19-9 levels in predicting the respectability of pancreatic carcinoma according to receiver operating characteristic (ROC) curve analysis.METHODS: Serum CA19-9 levels were measured in 104 patients with pancreatic cancer which were possible to be resected according to the imaging. ROC curve was plotted for the CA19-9 levels. The point closest to the upper left-hand corner of the graph were chosen as the cut-off point. The sensitivity, specificity, positive and negative predictive values of CA19-9 at this cut-off point were calculated.RESULTS: Resectable pancreatic cancer was detected in 58 (55.77%) patients and unresectable pancreatic cancer was detected in 46 (44.23%) patients. The area under the ROC curve was 0.918 and 95% CI was 0.843-0.992. The CA19-9 level was 353.15 U/mL, and the sensitivity and specificity of CA19-9 at this cut-off point were 93.1% and 78.3%, respectively. The positive and negative predictive value was 84.38% and 90%, respectively.CONCLUSION: Preoperative serum CA19-9 level is a useful marker for further evaluating the resectability of pancreatic cancer. Obviously increased serum levels of CA19-9 (> 353.15 U/mL) can be regarded as an ancillary parameter for unresectable pancreatic cancer.
机译：目的：根据接受者操作特征曲线分析评估血清CA19-9水平在预测胰腺癌可预见性方面的临床价值。方法：对104例胰腺癌患者进行血清CA19-9水平的测定根据影像切除。绘制了CA19-9水平的ROC曲线。选择最接近图形左上角的点作为截止点。结果：计算出CA19-9在这一临界点的敏感性，特异性，阳性和阴性预测值。结果：58例（55.77％）患者中检出可切除的胰腺癌，46例（44.23％）患者中检出不可切除的胰腺癌。 。 ROC曲线下的面积为0.918，95％CI为0.843-0.992。 CA19-9水平为353.15 U / mL，在此临界点时CA19-9的敏感性和特异性分别为93.1％和78.3％。结论：术前血清CA19-9水平可作为进一步评估胰腺癌可切除性的有用指标。血清CA19-9水平明显升高（> 353.15 U / mL）可以作为不可切除的胰腺癌的辅助指标。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱：kefu@zhangqiaokeyan.com

京公网安备：11010802029741号 ICP备案号：京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有

  • 客服微信

  • 服务号